Tag: clinical
MaaT Pharma: treatment of a first patient in the randomized Phase 2b clinical trial evaluating MaaT033 in patients receiving allo-HSCT
By Claude Leguilloux Published on 06/11/2023 at 08:01 a.m. Photo credit © Boursier.com (Boursier.com) — MaaT Pharmaa late-stage…
Aelis Farma: positive results from non-clinical regulatory studies for the entry of AEF0117 into a phase 3 clinical study – 07/11/2023 at 6:35 p.m.
Positive results from in vivo toxicological studies in which AEF0117 demonstrates a very favorable therapeutic index, more than 13,000 times higher than the active dose Finalization of the development of…
Innate Pharma: ASH 2023, presentation of new clinical data for Lacutamab and SAR443579/IPH6101
By Hector Chaunu Published on 03/11/2023 at 08:22 a.m. (Boursier.com) — Innate Pharma SA announces that the following…
France represents “13% of global clinical trials in oncology”, a platform created to list them
Romain Rouillard 8:00 p.m., October 10, 2023modified to 11:39 a.m., October 11, 2023 France, world champion in the fight against cancer? In any case, France is setting itself up as…
Nanobiotix: new clinical results at ESMO – 10/23/2023 at 12:15 p.m.
(CercleFinance.com) – Nanobiotix rose 4% this Monday on the Paris Stock Exchange after announcing new clinical results at the congress of the European Society of Oncology (ESMO). The conclusions of…
OSE Immuno: ‘very promising’ results from a clinical trial – 10/16/2023 at 09:37
(CercleFinance.com) – OSE Immunotherapeutics reported on Monday ‘very promising’ first results concerning a phase 1/2 clinical trial evaluating its monoclonal antibody in patients with solid tumors. According to the biotech,…
Ose immuno: ‘very promising’ results from a clinical trial
Read also (CercleFinance.com) – OSE Immunotherapeutics reported on Monday ‘very promising’ first results concerning a phase 1/2 clinical trial evaluating its monoclonal antibody in patients with solid tumors. According to…
Abionyx progresses: clinical data presented at the ASN congress in November – 10/16/2023 at 10:08 a.m.
(AOF) – Abionyx (+11% to 1.27 euros) announces that it has been selected to present phase 2 clinical data from the RACERS study at the Annual Congress of the American…
ABIONYX Pharma selected as Late-Breaking Clinical Results Poster Presentation during “Kidney Week” of the 2023 Annual Meeting of the American Society of Nephrology (ASN) for clinical data from the RACERS phase 2 study in sepsis – 16/10/2023 at 07:00
• The “Late-Breaking Clinical Results” session will present a world premiere of clinical data from the RACERS study in sepsis having achieved the primary and secondary objective of the study…
“It is urgent to invent new solutions adapted to their clinical and educational specificity”
DIn a class of twenty-eight children, it is estimated that on average, at least two students are affected by learning disorders, also called “dys disorders” because they include dyslexia, dyspraxia,…
PHAXIAM Therapeutics announces a high level of performance of its two anti-Staphylococcus aureus phages on clinical strains – 10/09/2023 at 10:05 p.m.
Data obtained from the phagogram developed by PHAXIAM, the first phage sensitivity test with CE marking, showed a response rate of 98% on 105 clinical strains of S. aureus. Lyon…
PHAXIAM Therapeutics announces a high level of performance of its two anti-Staphylococcus aureus phages on clinical strains – 10/09/2023 at 10:05 p.m.
PHAXIAM Therapeutics announces a high level of performance of its two anti- Staphylococcus aureus on clinical strains Data obtained from the phagogram developed by PHAXIAM, the first phage sensitivity test…